knee osteoarthritis patients perspectives on the reasons why an exercise program worked or didnt work for them A qualitative study
Not Applicable
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2024/04/066494
- Lead Sponsor
- Tanvi Shetkar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Individuals diagnosed with unilateral/bilateral knee osteoarthritis by orthopedician
2.Individuals with chronic knee osteoarthritis
3.Individuals who have taken minimum 5 sessions of physiotherapy treatment
4.Individuals willing to participate in the study
Either gender
Exclusion Criteria
1.Individuals with other musculoskeletal dysfunction in lower extremity in past 6 months
2.Individuals with neurological disorders
3.Individuals not willing to participate in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are influenced by exercise in knee osteoarthritis patients as explored in CTRI/2024/04/066494 qualitative study?
How do patient-reported outcomes from CTRI/2024/04/066494 compare with standard-of-care treatments like NSAIDs or hyaluronic acid injections for knee OA?
Which synovial fluid biomarkers correlate with exercise response in knee osteoarthritis patients according to CTRI/2024/04/066494 findings?
What adverse events are associated with structured exercise programs in knee osteoarthritis patients as identified in CTRI/2024/04/066494 observational study?
How does exercise intervention in CTRI/2024/04/066494 interact with pharmacological treatments like Tanezumab or COX-2 inhibitors in knee OA management?